58158
document
[ Afala in the treatment of patients with BPH : efficacy and safety ] . The double-blind , placebo-controlled , randomized clinical trial involving 94 patients has evaluated the efficacy and safety of domestic preparation afala in patients with symptoms of I-II stages benign prostatic hyperplasia ( BPH ) . It was shown that a 6-month course of treatment with afala at a dose of 2 tablets 4 times a day resulted in a significant reduction in the severity of urinary disorders , estimated by total IPSS score , relative to baseline values and compared to placebo therapy . The most pronounced therapeutic effects of the drug were registered in respect of irritative symptoms of BPH . According uroflowmetry , peak flow rate after 6 months of treatment was increased by more than 50 % . Significant clinical benefit persisted not only within the 6-month course of therapy , but 3 months after . Long-term therapy had no effect on the concentration of total , free and complex PSA , testosterone ( total and free ) , dihydrotestosterone , and prolactin in the blood . Absence of adverse effects , biochemical abnormalities , changes in clinical blood and urine confirmed the safety of 6-month therapy .
58159
Intervention_Pharmacological
[ Afala
58160
Intervention_Control
placebo-controlled
58161
Intervention_Pharmacological
afala
58162
Intervention_Pharmacological
afala at a dose of 2 tablets 4 times a day
58163
Intervention_Control
placebo
58164
Outcome_Physical
peak flow rate after
58165
Outcome_Physical
concentration of total , free and complex PSA
58166
Outcome_Physical
testosterone ( total and free ) , dihydrotestosterone
58167
Outcome_Physical
prolactin in the blood .
58168
Outcome_Adverse-effects
Absence of adverse effects , biochemical abnormalities , changes in clinical blood and urine
58169
Participant_Condition
BPH
58170
Participant_Condition
symptoms of I-II stages benign prostatic hyperplasia ( BPH )